Last updated on September 2018

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma


Brief description of study

The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Detailed Study Description

This is a multicenter, single-arm, open label, Phase 2 to evaluate efficacy, safety, pharmacokinetics and immunogenicity of E7777 in participants with relapsed or refractory PTCL and CTCL.

Clinical Study Identifier: NCT02676778

Contact Investigators or Research Sites near you

Start Over

Customer Joy Department. EJ

Eisai Trial Site #1
Fukuoka, Japan
  Connect »